7月30日，Abivax盘中上涨5.18%，报124.295美元/股，成交额5488.63万美元。
消息面上，摩根士丹利近日发布研报，将Abivax目标价从132美元大幅上调至180美元，维持"增持"评级。报告指出，公司核心药物obefazimod治疗溃疡性结肠炎的临床数据持续向好，专家对其疗效"一致看好"，认为该药物具有"广泛应用"的长期潜力，尤其在内镜指标方面表现突出。此外，此前市场对标签限制及监管风险的担忧已随临床数据改善而缓解。公司7月初完成约9.2亿美元ADS发行，资金可支撑运营至2029年第四季度，为obefazimod美国商业化提供充足弹药。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.